Citations

Clear

4610 citation(s) found for "Lu, Brian".

Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop
Go, Alan S. , Al‐Khatib, Sana M. , Desvigne‐Nickens, Patrice , Bansal, Nisha , Bushnell, Cheryl , Fang, Margaret C. , Freeman, James V. , Gage, Brian F. , Hanke, Thorsten , Singer, Daniel E. , Thomas, Kevin L. , Hills, Mellanie True , Turakhia, Mintu P. , Zieman, Susan J., Cooper, Lawton S. , Benjamin, Emelia J. , Bushnell, Cheryl D , Lopes, Renato D , Noseworthy, Peter A , Reddy, Vivek Y , Singer, Daniel E , Thomas, Kevin L , True Hills, Mellanie , Turakhia, Mintu P , Cooper, Lawton S , Benjamin, Emelia J , Freeman, James V , Al-Khatib, Sana M. , Hylek, Elaine M. , Lópes, Renato D. , Noseworthy, Peter A. , Reddy, Vivek Y.

Mayo Clinic

Stroke | February 27, 2023 | Volume: 54 | Issue: 3 | Pages: No page available

10.1161/strokeaha.121.038273 | PMID 36848427 Get It

Atrial fibrillation (AF) is one of the strongest risk factors for ischemic stroke, which is a leading cause of disability and death. Given the aging population, increasing prevalence of AF risk factors, and improved survival in those with cardiovascular disease, the number of individuals affected by AF will continue increasing over time. While multiple proven stroke prevention therapies exist, important questions remain about the optimal approach to stroke prevention at the population and individual patient levels. Our report summarizes the National Heart, Lung, and Blood Institute virtual workshop focused on identifying key research opportunities related to stroke prevention in AF. The workshop reviewed major knowledge gaps and identified targeted research opportunities to advance stroke prevention in AF in the following areas: (1) improving risk stratification tools for stroke and intracranial hemorrhage; (2) addressing challenges with oral anticoagulants; and (3) delineating the optimal roles of percutaneous left atrial appendage occlusion and surgical left atrial appendage closure/excision. This report aims to promote innovative, impactful research that will lead to more personalized, effective use of stroke prevention strategies in people with AF.
Change in Cerebrospinal Fluid Tau Microtubule Binding Region Detects Symptom Onset, Cognitive Decline, Tangles, and Atrophy in Dominantly Inherited Alzheimer's Disease
Li, Yan , Barthélemy, Nicolas R. , Gordon, Brian A. , Hassenstab, Jason , Fagan, Anne M. , Morris, John C. , Xiong, Chengjie , Méndez, Patricio Chrem, Noble, James M. , Farlow, Martin R. , Chhatwal, Jasmeer P. , Day, Gregory S. , Masters, Colin L. , Roh, Jee Hoon , Sachdev, Pallavi, Koyama, Akihiko , Reyderman, Larisa, Bateman, Randall J. , Network, and the Dominantly Inherited Alzheimer, Sachdev, Perminder S. , Vöglein, Jonathan , Gordon, Brian A , Kasuga, Kensaku , Day, Gregory S , Jucker, Mathias , Roh, Jee Hoon , Sato, Chihiro , McDade, Eric M , Sachdev, Perminder S , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Hassenstab, Jason , Morris, John C , Noble, James M , Horie, Kanta , Li, Yan, Benzinger, Tammie L.S. , Karch, Celeste M. , Xiong, Chengjie , Allegri, Ricardo , Ikeuchi, Takeshi , Schofield, Peter R. , Lee, Jae‐Hong , Sachdev, Pallavi, McDade, Eric , Network, and the Dominantly Inherited Alzheimer

Mayo Clinic

Annals of Neurology | February 27, 2023 | Volume: 93 | Issue: 6 | Pages: 1158-1172

10.1002/ana.26620 | PMID 36843330 Get It

ObjectiveIdentifying cerebrospinal fluid measures of the microtubule binding region of tau (MTBR‐tau) species that reflect tau aggregation could provide fluid biomarkers that track Alzheimer's disease related neurofibrillary tau pathological changes. We examined the cerebrospinal fluid (CSF) MTBR‐tau species in dominantly inherited Alzheimer's disease (DIAD) mutation carriers to assess the association with Alzheimer's disease (AD) biomarkers and clinical symptoms.MethodsCross‐sectional and longitudinal CSF from 229 DIAD mutation carriers and 130 mutation non‐carriers had sequential characterization of N‐terminal/mid‐domain phosphorylated tau (p‐tau) followed by MTBR‐tau species and tau positron emission tomography (tau PET), other soluble tau and amyloid biomarkers, comprehensive clinical and cognitive assessments, and brain magnetic resonance imaging of atrophy.ResultsCSF MTBR‐tau species located within the putative “border” region and one species corresponding to the “core” region of aggregates in neurofibrillary tangles (NFTs) increased during the presymptomatic stage and decreased during the symptomatic stage. The “border” MTBR‐tau species were associated with amyloid pathology and CSF p‐tau; whereas the “core” MTBR‐tau species were associated stronger with tau PET and CSF measures of neurodegeneration. The ratio of the border to the core species provided a continuous measure of increasing amounts that tracked clinical progression and NFTs.InterpretationChanges in CSF soluble MTBR‐tau species preceded the onset of dementia, tau tangle increase, and atrophy in DIAD. The ratio of 4R‐specific MTBR‐tau (border) to the NFT (core) MTBR‐tau species corresponds to the pathology of NFTs in DIAD and change with disease progression. The dynamics between different MTBR‐tau species in the CSF may serve as a marker of tau‐related disease progression and target engagement of anti‐tau therapeutics. ANN NEUROL 2023;93:1158–1172
Radiographic predictors of occult intracranial involvement in olfactory neuroblastoma patients
Geltzeiler, Mathew , Ji, Keven Seung Yong , JessMace, C., Almeida, John R. de , Champagne, Pierre‐Olivier , Chan, Erik, Ciporen, Jeremy , Chaskes, Mark B., Cornell, Sarah, Drozdowski, Veronica , Fernandez‐Miranda, Juan C. , Gardner, Paul A. , Hwang, Peter H. , Kalyvas, Aristotelis , Kong, Keonho A., McMillan, Ryan A. , Patel, Chirag , Patel, Zara M. , Celda, María Peris, Sanusi, Olabisi , Thorp, Brian D. , Zadeh, Gelareh , Zenonos, Georgios A. , Zwagerman, Nathan T. , Choby, Garret , Almeida, João Paulo , McMillan, Ryan A , Nayak, Jayakar V , Patel, Zara , Pinheiro-Neto, Carlos, Snyderman, Carl H , Wang, Eric W , Hwang, Peter H , Geltzeiler, Mathew , Choby, Garret , Nayak, Jayakar V. , Pinheiro‐Neto, Carlos , Gompel, Jamie J. Van

Mayo Clinic

International Forum of Allergy & Rhinology | February 26, 2023 | Volume: 13 | Issue: 10 | Pages: 1876-1888

10.1002/alr.23145 | PMID 36841933 Get It

AbstractBackgroundTraditional management of olfactory neuroblastoma (ONB) includes margin‐negative resection with removal of cribriform plate, dura, and olfactory bulb, regardless of intracranial disease. This approach may be overtreating certain patients. Our investigation examines risk factors associated with occult intracranial disease to optimize therapeutic outcomes.MethodsThis retrospective, multi‐institutional cohort study examined clinical covariates associated with occult intracranial involvement. Patient demographics, staging, Hyam's grade, and pathologic involvement of dura, olfactory bulb/tract, and brain were collected. Diagnostic imaging was reviewed. Positive and negative predictive value (NPV) were estimated along with effect size estimates. Cox hazard regression examined associations with overall survival (OS) and disease‐free survival (DFS).ResultsA total of 224 subjects with new diagnoses of ONB (2005–2021) were identified. Skull base bone involvement on computed tomography (CT) had the highest NPV for pathologic dura (88.0%), olfactory bulb (88%), and brain involvement (97.3%). Hyam's grade category was significantly associated with dural involvement (φC = 0.26; 95% confidence interval [CI]: 0.16, 0.42). Subjects without radiologic skull base involvement (n = 66) had pathologic positivity of 12.1%. Within this subgroup, Hyam's grade was clinically significant for dural positivity (φ = 0.34; 95% CI: −0.12, 0.71) with 28.6% involvement in high grade tumors. Neither clinical nor pathologic positivity of intracranial structures were associated with significantly different OS or DFS.ConclusionsBoth CT and magnetic resonance imaging (MRI) had reasonably good NPV for involvement of dura and olfactory bulb. Higher Hyam's grade was associated with dural involvement. Patients with low‐grade tumors not involving the skull base may be suitable for avoiding skull base resection; however, further investigation is warranted.
5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)
Neelapu, Sattva S. , Jacobson, Caron A. , Ghobadi, Armin , Miklos, David B. , Lekakis, Lazaros J. , Oluwole, Olalekan O. , Lin, Yi , Braunschweig, Ira , Hill, Brian T. , Timmerman, John M. , Deol, Abhinav , Stiff, Patrick J. , McSweeney, Peter A., Herrera, Alex F. , Bartlett, Nancy L. , Bot, Adrian A., Shen, Rhine R. , Dong, Jinghui , Singh, Kanwarjit, Miao, Harry , Zheng, Yan , Stiff, Patrick J , Flinn, Ian W , Farooq, Umar , Goy, Andre Henri , Munoz, Javier L , Herrera, Alex F , Bartlett, Nancy L , Oluwole, Olalekan O , Miklos, David B , Ghobadi, Armin , Reagan, Patrick Michael , Flinn, Ian W. , Muñoz, Javier , Siddiqi, Tanya , Chavez, Julio C , Bot, Adrian , Kim, Jaeyeon , Locke, Frederick L.

Mayo Clinic

Blood | February 23, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2022018893 | PMID 36821768 Get It

In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated durable responses at 2 years in patients with refractory large B-cell lymphoma (LBCL). Here, we aimed to assess survival and safety in ZUMA-1 after 5 years of follow-up. Eligible adults with refractory LBCL (diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and transformed follicular lymphoma) received lymphodepleting chemotherapy followed by axi-cel infusion targeted at 2×106 cells/kg. Investigator-assessed response, updated survival, safety, and pharmacokinetic outcomes were assessed in treated patients. The objective response rate in the 101 treated patients was 83% (58% complete response rate), and with a median follow-up of 63.1 months, responses were ongoing at data cutoff in 31%. Median overall survival (OS) was 25.8 months and the estimated 5-year OS rate was 42.6%. Disease-specific survival (excluding deaths unrelated to disease progression) estimated at 5 years was 51.0%. No new serious adverse events or deaths related to axi-cel were observed after additional follow-up. Peripheral blood B cells were detectable in all evaluable patients at 3 years with polyclonal B-cell recovery in 91%. Ongoing responses at 60 months were associated with early CAR T-cell expansion. In conclusion, this 5-year follow-up analysis of ZUMA-1 demonstrates sustained overall and disease-specific survival, with no new safety signals in patients with refractory LBCL. Protracted B-cell aplasia was not required for durable responses. These findings support the curative potential of axi-cel in a subset of patients with aggressive B-cell lymphomas. ClinicalTrials.gov, number NCT02348216
Demographic Characteristics Influence Treatment Costs of Invasive Melanoma in Florida
Spaulding, Aaron , Rinker, Brian, Huayllani, María T. , Maita, Karla C. , Ho, Olivia A. , Spaulding, Aaron C. , Torres-Guzman, Ricardo A, Spaulding, Aaron , Ávila, Francisco R. , Boczar, Daniel , Torres‐Guzman, Ricardo A. , Forte, Antonio J.

Mayo Clinic

Annals of Plastic Surgery | February 16, 2023 | Volume: 90 | Issue: 3 | Pages: 248-254

10.1097/sap.0000000000003422 | PMID 36796047 Get It

Background Demographic characteristics are known to influence the treatment and outcomes of patients with invasive melanoma. Whether these characteristics influence treatment costs is unknown. We aimed to analyze whether patient demographics and tumor characteristics influence treatment costs for patients with invasive cutaneous melanoma in Florida. Methods This was a cross-sectional study in which the Florida Inpatient and Outpatient Dataset of the Agency for Health Care Administration was analyzed for patients with a diagnosis of invasive melanoma between January 1, 2013 and December 31, 2018. Categorical variables were assessed using Pearson χ2 tests, and continuous variables were evaluated using Kruskal-Wallis tests. Logistic regression analysis was conducted to identify the association between patient demographics and total costs. All analyses were done using SAS 9.4 statistical software (SAS Institute, Inc). Results Multivariate analysis showed that sex (P < 0.001), hospital setting (P < 0.001), race/ethnicity (P < 0.01), patient region (P < 0.01), Elixhauser Comorbidity Index score (P < 0.001), presence of metastasis (P < 0.01), total number of procedures (P < 0.001), and length of stay (P < 0.001) were correlated with the cost of treatment of invasive cutaneous melanoma. After stratification, the association between cost and race/ethnicity disappeared for inpatients but remained for Black patients in the outpatient setting (P < 0.001). The association between cost and patient residence regions also differed when the cohort was stratified. Conclusions Strategies addressing disparities in treatment cost of invasive melanoma should differ, depending on the hospital setting where the patient is being treated.
Incidence of Glaucoma-Related Adverse Events in the First 5 Years After Pediatric Lensectomy
Bothun, Erick D. , Repka, Michael X. , Kraker, Raymond T. , Leske, David A. , Li, Zhuokai , Astle, William F., Holmes, Jonathan M. , Group, Pediatric Eye Disease Investigator, Wallace, David K. , Enyedi, Laura B. , Jones, Sarah K., Hug, Denise, Stahl, Erin D., Dent, Rebecca J., Kong, Lingkun , Wang, Serena , Gallerson, Bryan K., Hutchinson, Amy K., Lenhart, Phoebe D. , Brower, Judy, Morrison, David G., Ruark, Scott T., Mets-Halgrimson, Rebecca, Yoon, Hawke , Hamidullah, Aaliyah, Anderson, Jill S., Holleschau, Ann M., Superstein, Rosanne , Bélanger, Caroline, Fallaha, Nicole, Hamel, Patrick , Thibeault, Maryse, Tamkins, Susanna M. , Park, Hee-Jung S., Trumler, Anya A., Liu, Xiaonong, Sanders, Emi , McOwen, Diana C., Gray, Michael E. , Yang, Michael B. , Bowman, Corey S., Galvin, Jennifer, Therriault, Margaret, Smith, Heather , Whitaker, Michele E., Örge, Faruk , Grigorian, A. Paula, Baird, Alicia M., Strominger, Mitchell B. , Klein, Shelley, Kemmer, Jacquelyn D., Neiman, Alexandra E., Mendoza, Myra N., Frohwein, Jill J., Bremer, Don L., Cassady, Cybil, Golden, Richard P., Jordan, Catherine O., Oravec, Sara A., Yanovitch, Tammy L. , Lunsford, Keven, Nye, Christina, Shea, Caroline, Stillman, SueAnn M., Iderstine, Stephen C. Van, Robertson, Elisa, Cruz, Oscar A., Ghadban, Rafif, Govreau, Dawn, Longmuir, Susannah Q. , Shan, Xiaoyan, Taylor, Kate , Powell, Christine, Hammond, Benjamin P., Gearinger, Matthew D., Czubinski, Andrea, Salvin, Jonathan, Fisher, Alicia, Lee, Katherine A., Brooks, Daniel , Schweinler, Bonita R., Sala, Nicholas A., Sala, Allyson M., Summers, Allison I. , Karr, Daniel J. , Wilson, Lorri B., Rauch, Paula K., O’Hara, Mary, Gandhi, Nandini, Hashmi, Tania, Colburn, Jeffrey, Dittman, Eileen, Whitfill, Charles R., Wheeler, Amy M., McCourt, Emily A. , Singh, Jasleen , Welnick, Nanastasia, Azar, Nathalie F., Baker, Joseph, Droste, Patrick J. , Peters, Robert J., Hilbrands, Jan, Pineles, Stacy L., Bernardo, Marianne J., Peterson, Edward, Peterson, Charla H., Kumar, Kartik , Melese, Ephrem, Lingua, Robert W., Grijalva, Jeff, Crouch, Earl R., Crouch, Earl R., Ventura, Gaylord, Anninger, William, Benson, Shawn L., Karp, Karen A. , Smith, Jordana M., Brickman-Kelleher, Jill, Ticho, Benjamin H., Khammar, Alexander J., Clausius, Deborah A., Guo, Suquin, Chamberlain, Carolyn, Schloff, Susan, Madigan, William P., Burkman, Donna, Ramsey, Jean E., McConnell, Kate H. , Friedman, Ilana, Rosado, José , Sauberan, Donald P., Hemberger, Jody C., Davis, Patricia L., Rudaitis, Indre, Lowery, Robert S., Cupit, Shawn, Mohney, Brian G., Wernimont, Suzanne M., Neilsen, Rebecca A., Baran, Francine, Gladstone, Amy, Smith, Justin , Mellott, Mei, Kieser, Troy, Erzurum, S. Ayse , Colon, Beth, Shah, Birva, Quebbemann, Micaela, Austin, Darrell S., Boyle, Nicole M., Conner, Courtney L., Chandler, Danielle L. , Donahue, Quayleen, Fimbel, Brooke P., Robinson, Julianne L., Hercinovic, Amra, Hoepner, James E., Kaplon, Joseph D., Melia, Michele , Ortiz, Gillaine, Woodard, Victoria C., Stutz, Kathleen M., Sutherland, Desirae R. , Everett, Donald F., Diener‐West, Marie , Baker, John D., Davis, Barry R. , Phelps, Dale L. , Poff, Stephen W., Tychsen, Lawrence , Bradfield, Yasmin S., Foster, Nicole C. , Plager, David A. , Salchow, Daniel J. , Silver, Jayne L., Weise, Katherine K., Verderber, Lisa C. , Dean, Trevano W., Yen, Kimberly G., Campomanes, Alejandra G. de Alba , Young, Marielle P. , Rahmani, Bahram , Haider, Kathryn M. , Whitehead, George F., Lambert, Scott R. , Kurup, Sudhi P. , Kraus, Courtney L. , Wu, Rui, Hatt, Sarah R. , Freedman, Sharon F. , Cotter, Susan A. , Group, Pediatric Eye Disease Investigator, Prakalapakorn, Sasapin Grace , Ranaivo, Hantamalala Ralay , Areaux, Raymond G. , Chang, Ta Chen , Traboulsi, Elias I. , Ghasia, Fatema F. , Chen, Vicki, Rogers, David L. , LaRoche, G. Robert, Larson, Scott A. , Clarke, Michael W. , Hendricks, Dorothy H. , Jin, Jing , Brooks, Daniel, Rauch, Paula K., Baker, Joseph, Peterson, Edward, Crouch, Earl R., Suh, Donny Won , Christiansen, Stephen P. , Herlihy, Erin P. , Beck, Roy W. , Henderson, Robert J. , Saunders, Richard Anthony , Birch, Eileen E. , Manny, Ruth E. , Holmes, Jonathan M.

Mayo Clinic

JAMA Ophthalmology | February 16, 2023 | Volume: 141 | Issue: 4 | Pages: 324

10.1001/jamaophthalmol.2022.6413 | PMID 36795393 Get It

ImportanceGlaucoma can develop following cataract removal in children.ObjectiveTo assess the cumulative incidence of glaucoma-related adverse events (defined as glaucoma or glaucoma suspect) and factors associated with risk of these adverse events in the first 5 years after lensectomy prior to 13 years of age.Design, Setting, and ParticipantsThis cohort study used longitudinal registry data collected at enrollment and annually for 5 years from 45 institutional and 16 community sites. Participants were children aged 12 years or younger with at least 1 office visit after lensectomy from June 2012 to July 2015. Data were analyzed from February through December 2022.ExposuresUsual clinical care after lensectomy.Main Outcomes and MeasuresThe main outcomes were cumulative incidence of glaucoma-related adverse events and baseline factors associated with risk of these adverse events.ResultsThe study included 810 children (1049 eyes); 443 eyes of 321 children (55% female; mean [SD] age, 0.89 [1.97] years) were aphakic after lensectomy, and 606 eyes of 489 children (53% male; mean [SD] age, 5.65 [3.32] years) were pseudophakic. The 5-year cumulative incidence of glaucoma-related adverse events was 29% (95% CI, 25%-34%) in 443 eyes with aphakia and 7% (95% CI, 5%-9%) in 606 eyes with pseudophakia; 7% (95% CI, 5%-10%) of aphakic eyes and 3% (95% CI, 2%-5%) of pseudophakic eyes were diagnosed as glaucoma suspect. Among aphakic eyes, a higher risk for glaucoma-related adverse events was associated with 4 of 8 factors, including age less than 3 months (vs ≥3 months: adjusted hazard ratio [aHR], 2.88; 99% CI, 1.57-5.23), abnormal anterior segment (vs normal: aHR, 2.88; 99% CI, 1.56-5.30), intraoperative complications at time of lensectomy (vs none; aHR, 2.25; 99% CI, 1.04-4.87), and bilaterality (vs unilaterality: aHR, 1.88; 99% CI, 1.02-3.48). Neither of the 2 factors evaluated for pseudophakic eyes, laterality and anterior vitrectomy, were associated with risk of glaucoma-related adverse events.Conclusions and RelevanceIn this cohort study, glaucoma-related adverse events were common after cataract surgery in children; age less than 3 months at surgery was associated with elevated risk of the adverse events in aphakic eyes. Children with pseudophakia, who were older at surgery, less frequently developed a glaucoma-related adverse event within 5 years of lensectomy. The findings suggest that ongoing monitoring for the development of glaucoma is needed after lensectomy at any age.
Multi-Frequency Electrocochleography and Electrode Scan to Identify Electrode Insertion Trauma during Cochlear Implantation
Saoji, Aniket A. , Graham, Madison K., Adkins, Weston J., Koka, Kanthaiah , Carlson, Matthew L. , Neff, Brian A., Driscoll, Colin L. W., Fitzpatrick, Douglas C.

Mayo Clinic

Brain Sciences | February 15, 2023 | Volume: 13 | Issue: 2 | Pages: 330

10.3390/brainsci13020330 | PMID 36831873 Get It

Intraoperative electrocochleography (ECOG) is performed using a single low-frequency acoustic stimulus (e.g., 500 Hz) to monitor cochlear microphonics (CM) during cochlear implant (CI) electrode insertion. A decrease in CM amplitude is commonly associated with cochlear trauma and is used to guide electrode placement. However, advancement of the recording electrode beyond the sites of CM generation can also lead to a decrease in CM amplitude and is sometimes interpreted as cochlear trauma, resulting in unnecessary electrode manipulation and increased risk of cochlear trauma during CI electrode placement. In the present study, multi-frequency ECOG was used to monitor CM during CI electrode placement. The intraoperative CM tracings were compared with electrode scan measurements, where CM was measured for each of the intracochlear electrodes. Comparison between the peak CM amplitude measured during electrode placement and electrode scan measurements was used to differentiate between different mechanisms for decrease in CM amplitude during CI electrode insertion. Analysis of the data shows that both multi-frequency electrocochleography and electrode scan could potentially be used to differentiate between different mechanisms for decreasing CM amplitude and providing appropriate feedback to the surgeon during CI electrode placement.
Emerging approaches in neurostimulation for epilepsy
Osman, Gamaleldin , Starnes, Keith , Gregg, Nicholas M. , Osman, Gamaleldin M, Gregg, Nicholas M , Starnes, Donnie Keith , Lundstrom, Brian N. , Simpson, Hugh D.

Mayo Clinic

Current Opinion in Neurology | February 10, 2023 | Volume: 36 | Issue: 2 | Pages: 69-76

10.1097/wco.0000000000001138 | PMID 36762660 Get It

Purpose of review Neurostimulation is a quickly growing treatment approach for epilepsy patients. We summarize recent approaches to provide a perspective on the future of neurostimulation. Recent findings Invasive stimulation for treatment of focal epilepsy includes vagus nerve stimulation, responsive neurostimulation of the cortex and deep brain stimulation of the anterior nucleus of the thalamus. A wide range of other targets have been considered, including centromedian, central lateral and pulvinar thalamic nuclei; medial septum, nucleus accumbens, subthalamic nucleus, cerebellum, fornicodorsocommissure and piriform cortex. Stimulation for generalized onset seizures and mixed epilepsies as well as increased efforts focusing on paediatric populations have emerged. Hardware with more permanently implanted lead options and sensing capabilities is emerging. A wider variety of programming approaches than typically used may improve patient outcomes. Finally, noninvasive brain stimulation with its favourable risk profile offers the potential to treat increasingly diverse epilepsy patients. Summary Neurostimulation for the treatment of epilepsy is surprisingly varied. Flexibility and reversibility of neurostimulation allows for rapid innovation. There remains a continued need for excitability biomarkers to guide treatment and innovation. Neurostimulation, a part of bioelectronic medicine, offers distinctive benefits as well as unique challenges.
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium
Wang, Yucai , Jain, Preetesh , Locke, Frederick L. , Maurer, Matthew J. , Frank, Matthew J. , Muñoz, Javier , Dahiya, Saurabh , Beitinjaneh, Amer , Jacobs, Miriam T. , McGuirk, Joseph P. , Hill, Brian T. , Dorritie, Kathleen , Oluwole, Olalekan O. , Deol, Abhinav , Wang, Trent , Banerjee, Rahul , Miklos, David B. , Rapoport, Aaron P. , Lekakis, Lazaros J. , Neelapu, Sattva S. , Wang, Michael , Munoz, Javier L , Vose, Julie , Goy, Andre Henri , Oluwole, Olalekan O , Deol, Abhinav , Paludo, Jonas , Wang, Trent , Banerjee, Rahul , Miklos, David B , Rapoport, Aaron P , Neelapu, Sattva S , Lin, Yi , Wang, Michael L , Jain, Michael D , Maurer, Matthew , McGuirk, Joseph , Wang, Yucai , Dahiya, Saurabh , Jacobs, Miriam T , Locke, Frederick L , Jain, Preetesh , Vose, Julie M. , Andreadis, Charalambos Babis , Paludo, Jonas , Shah, Bijal , Ghobadi, Armin , Lin, Yi , Jain, Michael D.

Mayo Clinic

Journal of Clinical Oncology | February 8, 2023 | Volume: 41 | Issue: 14 | Pages: 2594-2606

10.1200/jco.22.01797 | PMID 36753699 Get It

PURPOSE Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell lymphoma (MCL). This therapy was approved on the basis of the single-arm phase II ZUMA-2 trial, which showed best overall and complete response rates of 91% and 68%, respectively. We report clinical outcomes with brexu-cel in the standard-of-care setting for the approved indication. PATIENTS AND METHODS Patients who underwent leukapheresis between August 1, 2020 and December 31, 2021, at 16 US institutions, with an intent to manufacture commercial brexu-cel for relapsed/refractory MCL, were included. Patient data were collected for analyses of responses, outcomes, and toxicities as per standard guidelines. RESULTS Of 189 patients who underwent leukapheresis, 168 (89%) received brexu-cel infusion. Of leukapheresed patients, 79% would not have met ZUMA-2 eligibility criteria. Best overall and complete response rates were 90% and 82%, respectively. At a median follow-up of 14.3 months after infusion, the estimates for 6- and 12-month progression-free survival (PFS) were 69% (95% CI, 61 to 75) and 59% (95% CI, 51 to 66), respectively. The nonrelapse mortality was 9.1% at 1 year, primarily because of infections. Grade 3 or higher cytokine release syndrome and neurotoxicity occurred in 8% and 32%, respectively. In univariable analysis, high-risk simplified MCL international prognostic index, high Ki-67, TP53 aberration, complex karyotype, and blastoid/pleomorphic variant were associated with shorter PFS after brexu-cel infusion. Patients with recent bendamustine exposure (within 24 months before leukapheresis) had shorter PFS and overall survival after leukapheresis in intention-to-treat univariable analysis. CONCLUSION In the standard-of-care setting, the efficacy and toxicity of brexu-cel were consistent with those reported in the ZUMA-2 trial. Tumor-intrinsic features of MCL, and possibly recent bendamustine exposure, may be associated with inferior efficacy outcomes.
Patient preferences for attributes of injected or infused preventive migraine medications: Findings from a discrete choice experiment
Martin, Ashley , Kymes, Steven , Talon, Brian , Lee, Xin Ying , Cady, Roger , Asher, Divya , Karnik‐Henry, Meghana , Mulvihill, Emily , Bates, Dawn, Beusterien, Kathleen , Martin, Ashley , Lee, Xin Ying , Asher, Divya , Schwedt, Todd J.

Mayo Clinic

Headache: The Journal of Head and Face Pain | February 8, 2023 | Volume: 63 | Issue: 4 | Pages: 484-493

10.1111/head.14476 | PMID 36753057 Get It

Abstract Objective To assess preferences among adults with migraine for differentiating attributes of injected or infused preventive treatment options and evaluate their importance in determining a treatment choice. Background Adults with migraine and health‐care providers consider many factors when making treatment decisions. Injected or infused preventive migraine treatment options differ in several attributes, including mode of administration and dosing frequency, which may be preferentially selected or avoided by patients. Understanding a patient's preference is important for clinicians as they advise on various treatment options. Methods A total of 604 US adults diagnosed with migraine participated in an online survey that captured information on demographics, migraine history, and treatment preferences. A discrete choice experiment (DCE) was used to evaluate participants’ preferences for specific attributes of injected/infused preventive migraine therapies. The DCE data were utilized to estimate attribute importance (expressed as a percentage) and identify subgroups that had different distributions of preferences. Results In the overall migraine population, mode of administration (28.8%), durability of effectiveness (27.0%), and speed of onset (25.5%) had the highest relative importance, whereas administration setting (9.9%) and dosing frequency (8.8%) had the lowest. Four distinct subgroups were identified: Group 1 ( n = 128) preferred self‐injection administration and durability of effectiveness; Group 2 ( n = 189) expressed aversion to cranial injections; Group 3 ( n = 158) prioritized rapid speed of onset; and Group 4 ( n = 129) favored health‐care provider administration and durability of effectiveness. Conclusions Speed of onset, durability of effectiveness, and mode of administration are key moderators of treatment preference among US adults with migraine. Certain segments of the migraine population prioritize specific treatment attributes over others, with intravenous infusion not considered a barrier in three of four identified segments. Clinicians can best help their patients find the right medication if they understand which medication attributes are most and least important to them.